Loading...
Receive $200 for creating an Interactive Brokers account using our link: Create IBKR account. Read our Interactive Brokers analysis
- Ticker
- NTLA
- Price
- 15.90
- Stock movement up
- +1.87 (13.33%)
- Company name
- Intellia Therapeutics Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 1.84B
- Ent value
- 1.83B
- Price/Sales
- 32.01
- Price/Book
- 2.46
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- 20.04%
- 1 year return (CAGR)
- 59.96%
- 3 year return (CAGR)
- -
- 5 year return (CAGR)
- -
- 10 year return (CAGR)
- -
Last updated: 2026-01-22
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
NTLA does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 32.01 |
| Price to Book | 2.46 |
| EV to Sales | 31.73 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 115.83M |
| EPS (TTM) | -4.05 |
| FCF per share (TTM) | -3.74 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 57.53M |
| Gross profit (TTM) | -21.42M |
| Operating income (TTM) | -478.73M |
| Net income (TTM) | -445.81M |
| EPS (TTM) | -4.05 |
| EPS (1y forward) | -3.59 |
Margins
Loading...
Margins data
| Gross margin (TTM) | -37.24% |
| Operating margin (TTM) | -832.16% |
| Profit margin (TTM) | -774.94% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 193.39M |
| Net receivables | 11.05M |
| Total current assets | 581.94M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 138.30M |
| Total assets | 925.27M |
| Accounts payable | 13.26M |
| Short/Current long term debt | 97.97M |
| Total current liabilities | 93.73M |
| Total liabilities | 176.85M |
| Shareholder's equity | 748.42M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -410.65M |
| Capital expenditures (TTM) | 1.98M |
| Free cash flow (TTM) | -412.63M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -59.57% |
| Return on Assets | -48.18% |
| Return on Invested Capital | -57.46% |
| Cash Return on Invested Capital | -53.19% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 14.03 |
| Daily high | 15.94 |
| Daily low | 13.76 |
| Daily Volume | 10.5M |
| All-time high | 176.78 |
| 1y analyst estimate | 22.43 |
| Beta | 2.13 |
| EPS (TTM) | -4.05 |
| Dividend per share | 0.00 |
| Ex-div date | - |
| Next earnings date | 19 Feb 2026 |
Downside potential
Loading...
Downside potential data
| NTLA | S&P500 | |
| Current price drop from All-time high | -91.01% | -0.89% |
| Highest price drop | -96.45% | -19.00% |
| Date of highest drop | 8 Apr 2025 | 8 Apr 2025 |
| Avg drop from high | -93.26% | -2.49% |
| Avg time to new high | - | 6 days |
| Max time to new high | 322 days | 89 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
1.84B
Marketcap category
Small-cap
Description
Intellia Therapeutics, Inc., a clinical-stage gene editing company, focuses on the development of curative genome editing treatments. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 that is in Phase 1/2 study for the treatment of hereditary angioedema. It also focusses on the research of proprietary programs focused on developing engineered cell therapies to treat various cancers and autoimmune diseases. The company has license and collaboration agreement with AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of various of B cell-mediated autoimmune diseases; ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer; and ReCode Therapeutics, Inc. to develop novel genomic medicines for the treatment of cystic fibrosis. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
Employees
403
Website
Investor relations
SEC filings
CEO
John M. Leonard
Country
USA
City
Cambridge
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page